期刊
NATURE REVIEWS GENETICS
卷 15, 期 2, 页码 82-92出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrg3563
关键词
-
资金
- New York State Stem Cell Board (NYSTEM) [C028503]
- US National Institute of Neurological Disorders [5R01NS054009, NS052671, NS084334]
After years of incremental progress, several recent studies have succeeded in deriving disease-relevant cell types from human pluripotent stem cell (hPSC) sources. The prospect of an unlimited cell source, combined with promising preclinical data, indicates that hPSC technology may be on the verge of clinical translation. In this Review, we discuss recent progress in directed differentiation, some of the new technologies that have facilitated the success of hPSC therapies and the remaining hurdles on the road towards developing hPSC-based cell therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据